PMC:7441788 / 39140-42371
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T128 | 367-375 | Body_part | denotes | endosome | http://purl.org/sig/ont/fma/fma67180 |
T129 | 1105-1109 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T130 | 2372-2376 | Body_part | denotes | milk | http://purl.org/sig/ont/fma/fma62100 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T23 | 2372-2376 | Body_part | denotes | milk | http://purl.obolibrary.org/obo/UBERON_0001913 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T159 | 16-24 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T160 | 244-252 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T161 | 541-549 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T162 | 657-665 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T163 | 693-701 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T164 | 796-804 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T165 | 903-911 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T166 | 1081-1086 | Disease | denotes | Ebola | http://purl.obolibrary.org/obo/MONDO_0005737 |
T167 | 1229-1240 | Disease | denotes | chikungunya | http://purl.obolibrary.org/obo/MONDO_0017941 |
T168 | 1296-1305 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T169 | 1443-1451 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T170 | 1489-1497 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T171 | 1867-1875 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T172 | 2143-2151 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T173 | 2457-2465 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T174 | 2468-2477 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T175 | 2857-2865 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T176 | 2992-3000 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T177 | 3116-3124 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T285 | 188-198 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activities |
T286 | 408-416 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T287 | 454-462 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T288 | 517-518 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T289 | 551-552 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T290 | 708-710 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
T291 | 769-777 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T292 | 1087-1092 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T293 | 1093-1109 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity in cell |
T294 | 1153-1159 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
T295 | 1192-1195 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T296 | 1241-1246 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T297 | 1264-1270 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
T298 | 1832-1834 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
T299 | 1837-1838 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T300 | 2267-2268 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T301 | 2324-2332 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T302 | 2395-2401 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
T303 | 2626-2631 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T304 | 2766-2767 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T409 | 157-159 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T410 | 310-312 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T411 | 599-601 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T412 | 781-783 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T413 | 857-859 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T414 | 1069-1071 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T415 | 1189-1191 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T416 | 1466-1468 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T417 | 2196-2198 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T418 | 2294-2296 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T419 | 2419-2421 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T420 | 2595-2607 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T421 | 2730-2732 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T422 | 2768-2777 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T423 | 2968-2970 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T424 | 3048-3059 | Chemical | denotes | application | http://purl.obolibrary.org/obo/CHEBI_33232 |
T425 | 3063-3065 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T426 | 3106-3111 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T22 | 1110-1117 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | culture | http://purl.bioontology.org/ontology/MEDDRA/10061447 |
T23 | 2525-2537 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | investigated | http://purl.bioontology.org/ontology/MEDDRA/10062026 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T240 | 157-159 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T241 | 310-312 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T242 | 599-601 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T243 | 781-783 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T244 | 857-859 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T245 | 1069-1071 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T246 | 1189-1191 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T247 | 1466-1468 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T248 | 2196-2198 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T249 | 2294-2296 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T250 | 2419-2421 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T251 | 2595-2607 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T252 | 2730-2732 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T253 | 2768-2777 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T254 | 2968-2970 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T255 | 3063-3065 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T139 | 16-24 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T140 | 244-254 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T141 | 541-549 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T142 | 657-665 | Species | denotes | SARS-CoV | NCBItxid:694009 |
T143 | 675-683 | Species | denotes | MERS-CoV | NCBItxid:1335626 |
T144 | 693-703 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T145 | 796-806 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T146 | 903-911 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T147 | 1081-1092 | Species | denotes | Ebola virus | NCBItxid:1570291 |
T148 | 1229-1246 | Species | denotes | chikungunya virus | NCBItxid:37124 |
T149 | 1443-1451 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T150 | 1489-1497 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T151 | 1867-1875 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T152 | 2143-2151 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T153 | 2269-2275 | Species | denotes | rodent | NCBItxid:9989 |
T154 | 2314-2323 | Species | denotes | HCoV-OC43 | NCBItxid:31631 |
T155 | 2395-2401 | Species | denotes | humans | NCBItxid:9605 |
T156 | 2457-2467 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T157 | 2857-2865 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T158 | 2992-3000 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T159 | 3116-3124 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T267 | 0-58 | Sentence | denotes | At present, the COVID-19 pandemic is continuing worldwide. |
T268 | 59-156 | Sentence | denotes | It is still an urgent need to find effective therapies and vaccines for treatment and prevention. |
T269 | 157-283 | Sentence | denotes | CQ/HCQ have diverse biological activities, and their mechanisms against CoVs including SARS-CoV-2 are not yet fully clarified. |
T270 | 284-463 | Sentence | denotes | Current studies show that CQ/HCQ can prevent receptor recognition by CoVs, inhibit endosome acidification, which interferes membrane fusion, and exhibit immunomodulatory activity. |
T271 | 464-550 | Sentence | denotes | These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. |
T272 | 551-712 | Sentence | denotes | A number of in vitro studies have revealed that CQ/HCQ have inhibitory effects on various CoVs, including SARS-CoV [12,13], MERS-CoV [10] and SARS-CoV-2 [16–18]. |
T273 | 713-815 | Sentence | denotes | However, conflicting results also exist on the in vitro activity of CQ/HCQ against SARS-CoV-2 [17,18]. |
T274 | 816-1030 | Sentence | denotes | Several clinical studies have shown that CQ/HCQ may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay the progression of the disease, with less serious adverse effects [48,50,57,58,]. |
T275 | 1031-1175 | Sentence | denotes | However, previous studies showed that CQ had anti-Ebola virus activity in cell culture, but it had conflicting results in animal models [71,72]. |
T276 | 1176-1340 | Sentence | denotes | In addition, CQ has shown beneficial results against chikungunya virus in vitro, but in animal models it aggravates the infection and lacks therapeutic effect [73]. |
T277 | 1341-1586 | Sentence | denotes | More importantly, in recent studies the use of HCQ did not show any favorable effect on patients with COVID-19 and high-dose CQ treatment of severe COVID-19 patients may even increase the risks of mortality and QTc interval prolongation [49,55]. |
T278 | 1587-1674 | Sentence | denotes | In addition, the optimal daily dose and duration of treatment course are not yet clear. |
T279 | 1675-1836 | Sentence | denotes | One study suggested that the dose of HCQ should be 400 mg/2 times for 1 day, 200 mg/2 times/day for 4 days based on the physiological pharmacokinetic model [18]. |
T280 | 1837-2173 | Sentence | denotes | A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]. |
T281 | 2174-2266 | Sentence | denotes | Whether the dosage of CQ or HCQ should be varied according disease severity is also unclear. |
T282 | 2267-2382 | Sentence | denotes | A rodent study showed that CQ could exert anti-HCoV-OC43 activity transplacentally or by way of maternal milk [14]. |
T283 | 2383-2538 | Sentence | denotes | However, in humans, the efficacy of CQ in the prevention and treatment of SARS-CoV-2 infection to both the mother and the child remains to be investigated. |
T284 | 2539-2716 | Sentence | denotes | Clinical trials in France showed that HCQ combined with azithromycin could enhance the virus clearance [50], but the subsequent reports did not support this combination [59,61]. |
T285 | 2717-2887 | Sentence | denotes | Furthermore, CQ/HCQ alone or in combination with a macrolide induced high rate of adverse effects, especially prolonged QTc, in the use for COVID-19 treatment [61,68,69]. |
T286 | 2888-3231 | Sentence | denotes | Therefore, current data are not sufficient enough to support the routine use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken for the application of CQ/HCQ, alone or in combination with other drugs, in COVID-19 before the conclusive findings are obtained by well-designed, multicenter, randomized, controlled studies. |
LitCovid-sample-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T21 | 2372-2376 | Body_part | denotes | milk | http://purl.obolibrary.org/obo/UBERON_0001913 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
1478 | 857-863 | Gene | denotes | CQ/HCQ | |
1479 | 781-787 | Gene | denotes | CQ/HCQ | |
1480 | 229-233 | Species | denotes | CoVs | Tax:11118 |
1481 | 244-254 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1482 | 353-357 | Species | denotes | CoVs | Tax:11118 |
1483 | 641-645 | Species | denotes | CoVs | Tax:11118 |
1484 | 657-665 | Species | denotes | SARS-CoV | Tax:694009 |
1487 | 796-806 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1488 | 1229-1246 | Species | denotes | chikungunya virus | Tax:37124 |
1489 | 1429-1437 | Species | denotes | patients | Tax:9606 |
1490 | 1498-1506 | Species | denotes | patients | Tax:9606 |
1491 | 1876-1884 | Species | denotes | patients | Tax:9606 |
1492 | 2152-2160 | Species | denotes | patients | Tax:9606 |
1493 | 2395-2401 | Species | denotes | humans | Tax:9606 |
1494 | 2505-2510 | Species | denotes | child | Tax:9606 |
1495 | 1081-1086 | Species | denotes | Ebola | Tax:1570291 |
1496 | 2314-2323 | Species | denotes | HCoV-OC43 | Tax:31631 |
1497 | 157-163 | Chemical | denotes | CQ/HCQ | |
1498 | 310-316 | Chemical | denotes | CQ/HCQ | |
1499 | 599-601 | Chemical | denotes | CQ | MESH:D002738 |
1500 | 602-605 | Chemical | denotes | HCQ | MESH:D006886 |
1501 | 1069-1071 | Chemical | denotes | CQ | MESH:D002738 |
1502 | 1189-1191 | Chemical | denotes | CQ | MESH:D002738 |
1503 | 1388-1391 | Chemical | denotes | HCQ | MESH:D006886 |
1504 | 1466-1468 | Chemical | denotes | CQ | MESH:D002738 |
1505 | 1712-1715 | Chemical | denotes | HCQ | MESH:D006886 |
1506 | 1860-1863 | Chemical | denotes | HCQ | MESH:D006886 |
1507 | 2053-2056 | Chemical | denotes | HCQ | MESH:D006886 |
1508 | 2196-2198 | Chemical | denotes | CQ | MESH:D002738 |
1509 | 2202-2205 | Chemical | denotes | HCQ | MESH:D006886 |
1510 | 2294-2296 | Chemical | denotes | CQ | MESH:D002738 |
1511 | 2419-2421 | Chemical | denotes | CQ | MESH:D002738 |
1512 | 2577-2580 | Chemical | denotes | HCQ | MESH:D006886 |
1513 | 2595-2607 | Chemical | denotes | azithromycin | MESH:D017963 |
1514 | 2730-2736 | Chemical | denotes | CQ/HCQ | |
1515 | 2768-2777 | Chemical | denotes | macrolide | MESH:D018942 |
1516 | 2968-2970 | Chemical | denotes | CQ | MESH:D002738 |
1517 | 2971-2974 | Chemical | denotes | HCQ | MESH:D006886 |
1518 | 3063-3065 | Chemical | denotes | CQ | MESH:D002738 |
1519 | 3066-3069 | Chemical | denotes | HCQ | MESH:D006886 |
1520 | 16-24 | Disease | denotes | COVID-19 | MESH:C000657245 |
1521 | 541-549 | Disease | denotes | COVID-19 | MESH:C000657245 |
1522 | 903-911 | Disease | denotes | COVID-19 | MESH:C000657245 |
1523 | 1296-1305 | Disease | denotes | infection | MESH:D007239 |
1524 | 1443-1451 | Disease | denotes | COVID-19 | MESH:C000657245 |
1525 | 1489-1497 | Disease | denotes | COVID-19 | MESH:C000657245 |
1526 | 1538-1547 | Disease | denotes | mortality | MESH:D003643 |
1527 | 1552-1577 | Disease | denotes | QTc interval prolongation | MESH:D008133 |
1528 | 1867-1875 | Disease | denotes | COVID-19 | MESH:C000657245 |
1529 | 2143-2151 | Disease | denotes | COVID-19 | MESH:C000657245 |
1530 | 2457-2477 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
1531 | 2857-2865 | Disease | denotes | COVID-19 | MESH:C000657245 |
1532 | 2992-3000 | Disease | denotes | COVID-19 | MESH:C000657245 |
1533 | 3116-3124 | Disease | denotes | COVID-19 | MESH:C000657245 |
690 | 2733-2736 | Chemical | denotes | HCQ | MESH:D006886 |
695 | 2971-2974 | Chemical | denotes | HCQ | MESH:D006886 |
719 | 3116-3124 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T147 | 891-899 | http://purl.obolibrary.org/obo/OGMS_0000020 | denotes | symptoms |
T148 | 972-979 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | disease |
T149 | 1087-1092 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T150 | 1105-1109 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
T151 | 1241-1246 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T152 | 1296-1305 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infection |
T153 | 2233-2240 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | disease |
T154 | 2468-2477 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infection |
T155 | 2626-2631 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T127 | 367-375 | Body_part | denotes | endosome | http://purl.org/sig/ont/fma/fma67180 |
T128 | 1105-1109 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T129 | 2372-2376 | Body_part | denotes | milk | http://purl.org/sig/ont/fma/fma62100 |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T77 | 376-389 | http://purl.obolibrary.org/obo/GO_0045851 | denotes | acidification |
T78 | 408-423 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T151 | 16-24 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T152 | 244-254 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T153 | 541-549 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T154 | 657-665 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T155 | 693-703 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T156 | 796-806 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T157 | 903-911 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T158 | 1081-1086 | Disease | denotes | Ebola | http://purl.obolibrary.org/obo/MONDO_0005737 |
T159 | 1229-1240 | Disease | denotes | chikungunya | http://purl.obolibrary.org/obo/MONDO_0017941 |
T160 | 1296-1305 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T161 | 1443-1451 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T162 | 1489-1497 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T163 | 1867-1875 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T164 | 2143-2151 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T165 | 2457-2467 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T166 | 2468-2477 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T167 | 2857-2865 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T168 | 2992-3000 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T169 | 3116-3124 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T68 | 376-389 | http://purl.obolibrary.org/obo/GO_0045851 | denotes | acidification |
T69 | 408-423 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T64 | 376-389 | http://purl.obolibrary.org/obo/GO_0045851 | denotes | acidification |
T65 | 408-423 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
690 | 2733-2736 | Chemical | denotes | HCQ | MESH:D006886 |
1478 | 857-863 | Gene | denotes | CQ/HCQ | |
1479 | 781-787 | Gene | denotes | CQ/HCQ | |
1480 | 229-233 | Species | denotes | CoVs | Tax:11118 |
1481 | 244-254 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1482 | 353-357 | Species | denotes | CoVs | Tax:11118 |
1483 | 641-645 | Species | denotes | CoVs | Tax:11118 |
1484 | 657-665 | Species | denotes | SARS-CoV | Tax:694009 |
1485 | 675-683 | Species | denotes | MERS-CoV | Tax:1335626 |
1486 | 693-703 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1487 | 796-806 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1488 | 1229-1246 | Species | denotes | chikungunya virus | Tax:37124 |
1489 | 1429-1437 | Species | denotes | patients | Tax:9606 |
1490 | 1498-1506 | Species | denotes | patients | Tax:9606 |
1491 | 1876-1884 | Species | denotes | patients | Tax:9606 |
1492 | 2152-2160 | Species | denotes | patients | Tax:9606 |
1493 | 2395-2401 | Species | denotes | humans | Tax:9606 |
1494 | 2505-2510 | Species | denotes | child | Tax:9606 |
1495 | 1081-1086 | Species | denotes | Ebola | Tax:1570291 |
1496 | 2314-2323 | Species | denotes | HCoV-OC43 | Tax:31631 |
1497 | 157-163 | Chemical | denotes | CQ/HCQ | |
1498 | 310-316 | Chemical | denotes | CQ/HCQ | |
1499 | 599-601 | Chemical | denotes | CQ | MESH:D002738 |
1500 | 602-605 | Chemical | denotes | HCQ | MESH:D006886 |
1501 | 1069-1071 | Chemical | denotes | CQ | MESH:D002738 |
1502 | 1189-1191 | Chemical | denotes | CQ | MESH:D002738 |
1503 | 1388-1391 | Chemical | denotes | HCQ | MESH:D006886 |
1504 | 1466-1468 | Chemical | denotes | CQ | MESH:D002738 |
1505 | 1712-1715 | Chemical | denotes | HCQ | MESH:D006886 |
1506 | 1860-1863 | Chemical | denotes | HCQ | MESH:D006886 |
1507 | 2053-2056 | Chemical | denotes | HCQ | MESH:D006886 |
1508 | 2196-2198 | Chemical | denotes | CQ | MESH:D002738 |
1509 | 2202-2205 | Chemical | denotes | HCQ | MESH:D006886 |
1510 | 2294-2296 | Chemical | denotes | CQ | MESH:D002738 |
1511 | 2419-2421 | Chemical | denotes | CQ | MESH:D002738 |
1512 | 2577-2580 | Chemical | denotes | HCQ | MESH:D006886 |
1513 | 2595-2607 | Chemical | denotes | azithromycin | MESH:D017963 |
1514 | 2730-3069 | Chemical | denotes | CQ/HCQ alone or in combination with a macrolide induced high rate of adverse effects, especially prolonged QTc, in the use for COVID-19 treatment [61,68,69]. Therefore, current data are not sufficient enough to support the routine use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken for the application of CQ/HCQ | |
1515 | 2779-2788 | Chemical | denotes | nduced hi | MESH:D018942 |
1516 | 2968-2970 | Chemical | denotes | CQ | MESH:D002738 |
1517 | 2971-2974 | Chemical | denotes | HCQ | MESH:D006886 |
1518 | 3063-3065 | Chemical | denotes | CQ | MESH:D002738 |
1519 | 3066-3069 | Chemical | denotes | HCQ | MESH:D006886 |
1520 | 16-24 | Disease | denotes | COVID-19 | MESH:C000657245 |
1521 | 541-549 | Disease | denotes | COVID-19 | MESH:C000657245 |
1522 | 903-911 | Disease | denotes | COVID-19 | MESH:C000657245 |
1523 | 1296-1305 | Disease | denotes | infection | MESH:D007239 |
1524 | 1443-1451 | Disease | denotes | COVID-19 | MESH:C000657245 |
1525 | 1489-1497 | Disease | denotes | COVID-19 | MESH:C000657245 |
1526 | 1538-1547 | Disease | denotes | mortality | MESH:D003643 |
1527 | 1552-1577 | Disease | denotes | QTc interval prolongation | MESH:D008133 |
1528 | 1867-1875 | Disease | denotes | COVID-19 | MESH:C000657245 |
1529 | 2143-2151 | Disease | denotes | COVID-19 | MESH:C000657245 |
1530 | 2457-2477 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
1531 | 2868-2876 | Disease | denotes | eatment | MESH:C000657245 |
1532 | 2992-3000 | Disease | denotes | COVID-19 | MESH:C000657245 |
1533 | 3116-3124 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T267 | 0-58 | Sentence | denotes | At present, the COVID-19 pandemic is continuing worldwide. |
T268 | 59-156 | Sentence | denotes | It is still an urgent need to find effective therapies and vaccines for treatment and prevention. |
T269 | 157-283 | Sentence | denotes | CQ/HCQ have diverse biological activities, and their mechanisms against CoVs including SARS-CoV-2 are not yet fully clarified. |
T270 | 284-463 | Sentence | denotes | Current studies show that CQ/HCQ can prevent receptor recognition by CoVs, inhibit endosome acidification, which interferes membrane fusion, and exhibit immunomodulatory activity. |
T271 | 464-550 | Sentence | denotes | These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. |
T272 | 551-712 | Sentence | denotes | A number of in vitro studies have revealed that CQ/HCQ have inhibitory effects on various CoVs, including SARS-CoV [12,13], MERS-CoV [10] and SARS-CoV-2 [16–18]. |
T273 | 713-815 | Sentence | denotes | However, conflicting results also exist on the in vitro activity of CQ/HCQ against SARS-CoV-2 [17,18]. |
T274 | 816-1030 | Sentence | denotes | Several clinical studies have shown that CQ/HCQ may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay the progression of the disease, with less serious adverse effects [48,50,57,58,]. |
T275 | 1031-1175 | Sentence | denotes | However, previous studies showed that CQ had anti-Ebola virus activity in cell culture, but it had conflicting results in animal models [71,72]. |
T276 | 1176-1340 | Sentence | denotes | In addition, CQ has shown beneficial results against chikungunya virus in vitro, but in animal models it aggravates the infection and lacks therapeutic effect [73]. |
T277 | 1341-1586 | Sentence | denotes | More importantly, in recent studies the use of HCQ did not show any favorable effect on patients with COVID-19 and high-dose CQ treatment of severe COVID-19 patients may even increase the risks of mortality and QTc interval prolongation [49,55]. |
T278 | 1587-1674 | Sentence | denotes | In addition, the optimal daily dose and duration of treatment course are not yet clear. |
T279 | 1675-1836 | Sentence | denotes | One study suggested that the dose of HCQ should be 400 mg/2 times for 1 day, 200 mg/2 times/day for 4 days based on the physiological pharmacokinetic model [18]. |
T280 | 1837-2173 | Sentence | denotes | A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]. |
T281 | 2174-2266 | Sentence | denotes | Whether the dosage of CQ or HCQ should be varied according disease severity is also unclear. |
T282 | 2267-2382 | Sentence | denotes | A rodent study showed that CQ could exert anti-HCoV-OC43 activity transplacentally or by way of maternal milk [14]. |
T283 | 2383-2538 | Sentence | denotes | However, in humans, the efficacy of CQ in the prevention and treatment of SARS-CoV-2 infection to both the mother and the child remains to be investigated. |
T284 | 2539-2716 | Sentence | denotes | Clinical trials in France showed that HCQ combined with azithromycin could enhance the virus clearance [50], but the subsequent reports did not support this combination [59,61]. |
T285 | 2717-2887 | Sentence | denotes | Furthermore, CQ/HCQ alone or in combination with a macrolide induced high rate of adverse effects, especially prolonged QTc, in the use for COVID-19 treatment [61,68,69]. |
T286 | 2888-3231 | Sentence | denotes | Therefore, current data are not sufficient enough to support the routine use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken for the application of CQ/HCQ, alone or in combination with other drugs, in COVID-19 before the conclusive findings are obtained by well-designed, multicenter, randomized, controlled studies. |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32496926-15351731-132195715 | 667-669 | 15351731 | denotes | 12 |
32496926-16115318-132195716 | 670-672 | 16115318 | denotes | 13 |
32496926-24841269-132195717 | 685-687 | 24841269 | denotes | 10 |
32496926-32020029-132195718 | 705-707 | 32020029 | denotes | 16 |
32496926-32194981-132195718 | 705-707 | 32194981 | denotes | 16 |
32496926-32194981-132195719 | 808-810 | 32194981 | denotes | 17 |
32496926-23577127-132195720 | 1168-1170 | 23577127 | denotes | 71 |
32496926-26459826-132195721 | 1171-1173 | 26459826 | denotes | 72 |
32496926-19506054-132195722 | 2378-2380 | 19506054 | denotes | 14 |